OVERVIEW

Schizophrenia represents a major psychiatric disorder characterized by symptoms that frequently compromise daily functioning and diminish overall quality of life. While effective management can lead to improved patient outcomes, many individuals continue to struggle with persistent or residual symptoms, medication compliance challenges, and adverse drug reactions. In particular, poor adherence to oral antipsychotic treatment increases the likelihood of symptom recurrence and psychiatric hospitalization. To address these challenges, long-acting injectable(LAI) antipsychotic formulations have been developed, offering advantages such as eliminating the need for daily medication administration, maintaining more stable drug levels in the bloodstream, and facilitating consistent clinical oversight.

This educational program brings together clinical experts to examine how long-acting injectable antipsychotics can be effectively utilized in schizophrenia treatment, emphasizing their therapeutic benefits and safety profiles while exploring optimal strategies for incorporating these medications into personalized patient care approaches.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

OVERVIEW

This educational program brings together renowned experts in treating major depressive disorder (MDD). In this educational program, these experts discuss managing patients with MDD by reviewing patient scenarios, reflecting on how to handle challenging cases, and integrating relevant evidence into real-world patient management.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

OVERVIEW

The muscarinic system plays a critical role in cognition, perception, and dopaminergic regulation. Postmortem and imaging studies suggest that cholinergic dysfunction, particularly involving the M1 and M4 receptor subtypes, contributes to schizophrenia pathophysiology. Stimulation of these receptors may help normalize dopaminergic signaling in key brain regions without directly blocking dopamine receptors, potentially reducing psychosis while improving cognition and negative symptoms. Muscarinic receptor modulators represent shift in schizophrenia treatment—offering a mechanism distinct from dopamine antagonism and addressing unmet needs in symptom control and tolerability.  

In this live expert Illustrations & Commentaries™ activity experts will discuss how the rationale for  muscarinic receptor modulation clinical data and use of the xanomeline/trospium chloride, the recently approved therapy in this class for management of schizophrenia.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to: